Tumor Marker Doubling Time in
Patients with Prostate Cancer:
Determination of Prostate-Specific
Antigen and Prostatic Acid
Phosphatase Doubling Time

Akimoto, Susumu; Masai, Motoyuki; Akakura, Koichiro; Shimazaki, Jun

doi:10.1159/000475162

Cited by 32 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After intensive hormone therapy (such as MAB) for metastatic disease, patients showed a much shorter PSA‐DT after relapse. Patients in the hormone refractory state showed PSA‐DT of 2.1 ± 1.6 months 14 . A similar trend was reported for patients with metastatic disease; PSA‐DT was 9.4 ± 1.1 months before androgen ablation and 3.9 ± 0.4 months in the hormone refractory state 25 .…”

Section: Discussionsupporting

confidence: 77%

“…In cases of low‐risk prostate cancer, in which watchful waiting is indicated, PSA‐DT was found to be approximately 24–36 months and in some cases was up to 120 months. Untreated cases of stage B2‐C cancer showed PSA‐DT of 27.9 ± 11.6 months 14 . Before radiation therapy, patients with T1‐3 cancer showing PSA‐DT of 60 months or more, resulted in only 3% of relapse by 3 years 15 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Significance of prostate‐specific antigen‐doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: Analysis on 56 cases of cancer‐specific death

et al. 2007

Self Cite

View full text Add to dashboard Cite

Objective: Most of the metastatic diseases initially respond to maximum androgen blockade, but then relapse and lose response, and finally die. After relapse, the disease progresses in various courses. The present study was aimed to establish the predicting factors influencing the survival period of patients at prostate-specific antigen (PSA) relapse (entering the hormone refractory state). Materials and Methods: Fifty-six patients with prostate cancer and bone metastasis, who were treated during the entire disease period at the same hospital and died were studied. To calculate PSA-doubling time, assay of PSA was carried out every 3 months or less. Results: The period between PSA relapse and death was related with PSA-doubling time at relapse, nadir PSA and the period between the start of treatment and PSA relapse. The PSA-doubling time of 2 months or less at relapse was suggestive of a poor outcome. Final PSA-doubling time was not correlated with the survival period after PSA relapse. Conclusion:The PSA-doubling time at relapse is one of the relevant factors for predicting the survival period after PSA relapse.

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Significance of prostate‐specific antigen‐doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: Analysis on 56 cases of cancer‐specific death

et al. 2007

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, PSA density [77,78], PSA slope [79], PSA doubling time [80,81], and free PSA [82] have been measured and calculated in trying to improve the sensitivity and specificity of PSA testing, and, to certain extent, they provide an improvement [reviewed in Ref. 31].…”

Section: Prostate-specific Antigenmentioning

confidence: 99%

Diagnostic and prognostic markers for human prostate cancer

et al. 1997

View full text Add to dashboard Cite

BACKGROUND The incidence and mortality of prostate cancer are increasing at alarming rates, partially due to an aging population. Early detection of prostate cancer, using clinically sensitive procedures and/or tumor markers (e.g., prostate‐specific antigen [PSA]), is of prime importance. However, the choice of therapeutic interventions for prostate cancer at the time of diagnosis is largely dependent on clinical and pathologic staging and prediction of the degree of aggressiveness of the disease. Clinically applicable prognostic markers are urgently needed to assist in the selection of optimal therapy. METHODS Literature review of the potential diagnostic and prognostic markers for human prostate cancer. RESULTS Well‐established tissue prognostic indicators, including histologic grade, margin positivity, pathologic stage, intraglandular tumor extent, and DNA ploidy, are not reviewed in this paper. Recently, a number of novel markers have been identified. In this paper, we begin with a discussion of a number of well‐established as well as investigational diagnostic markers and then focus on evaluation of prognostic markers. Diagnostic markers that have prognostic value and investigational prognostic markers are also discussed. CONCLUSIONS Currently, only PSA is utilized for early diagnosis and monitoring of prostate cancer. A number of potential prognostic markers warrant further investigation. Multimarker analysis is implicated. Prostate 31:264–281, 1997.© 1997 Wiley‐Liss, Inc.

show abstract

“…PSA-DT has emerged as an easily obtainable and clinically relevant prognostic marker in several stages of prostate cancer, including pre-prostatectomy, pre-radiation therapy, rising PSA after local therapy, nonmetastatic HRPC and, most recently, metastatic HRPC [14][15][16][17][18]. In the TAX 327 study, a multivariate prognostic model incorporating PSA kinetics has been developed to predict survival at 1, 2 and 5 years in metastatic HRPC men treated with chemotherapy [19].…”

Section: Predictive Models In Hrpcmentioning

confidence: 99%

Predictive modelling in hormone-refractory prostate cancer (HRPC)

2009

View full text Add to dashboard Cite

Because the evidence is not yet solid enough to strongly recommend whether or not to treat hormone-refractory prostate cancer (HRPC) patients at certain stages of the disease, predictive models might help in decision making. The importance of prognostic models lies in their ability to capture clinically relevant and measurable variables for routine use by clinicians to inform patients, and improve palliation and treatment decisions. Basically this allows for the creation of homogeneous prognostic strata for randomised comparative trials of therapeutic agents. In the last few years different models to predict patient outcome in HRPC have been published in the literature. Recently, based on the phase III randomised trial of docetaxel, a multivariate prognostic model incorporating PSA kinetics has been developed to predict survival at 1, 2 and 5 years in metastatic HRPC men treated with chemotherapy. This novel model includes new independent clinical prognostic factors in addition to PSA-DT such as baseline pain, type of progression at baseline (measurable disease or bone scan compared with PSA only), presence of liver metastases and the number of metastatic disease sites. This nomogram will be a helpful tool to stratify patients for further docetaxel-based trials and could also help us to delineate the potential benefits of chemotherapy at certain points during the natural history of HRPC.

show abstract

Tumor Marker Doubling Time in Patients with Prostate Cancer: Determination of Prostate-Specific Antigen and Prostatic Acid Phosphatase Doubling Time

Cited by 32 publications

References 12 publications

Significance of prostate‐specific antigen‐doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: Analysis on 56 cases of cancer‐specific death

Significance of prostate‐specific antigen‐doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: Analysis on 56 cases of cancer‐specific death

Diagnostic and prognostic markers for human prostate cancer

Predictive modelling in hormone-refractory prostate cancer (HRPC)

Contact Info

Product

Resources

About